Introduction

Engagement of the programmed cell death 1 (PD-1) receptor by its ligand, programmed death ligand 1 (PD-L1), has been demonstrated in studies to downregulate T-cell mediated immune responses (1-4). Early preclinical evidence supported the use of PD-1/PD-L1 inhibition as a potential mechanism for cancer immunotherapy as cancer cells have been known to evade host immune defenses with activation of PD-1/PD-L1 (3,5,6). Results from early clinical trials of humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in patients with advanced solid tumors led to the first US Food and Drug Administration (FDA)-approved PD-1 inhibitors, pembrolizumab and nivolumab (7-9). Cancers of the stomach and esophagus are responsible for >60% of total cases and deaths worldwide with an estimated 1.5 million cases of gastroesophageal cancer leading to 1.1 million deaths globally in 2012 (10). Despite sequencing of available active systemic agents, prognosis remains poor in advanced disease with a median overall survival (OS) of 8–10 months where approximately 2/3 of patients with gastroesophageal cancer develop metastatic disease during the course of their disease (11). Even with the increasing prevalence of PD-1/PD-L1 inhibitors in cancer treatment, it was not until late 2017 when the FDA first approved the use of PD-1 inhibition in advanced gastroesophageal cancer (12). In this review, we discuss the rationale and results thus far available from phase I-III trials supporting the activity of PD-1 inhibitors in advanced or metastatic gastroesophageal cancer.
gastroesophageal cancer. In addition, we highlight the clinical development of PD-1 inhibitors leading up to the recent approval of pembrolizumab in advanced gastroesophageal cancer. Finally, we will review the current molecular understanding and potential role of molecular subtyping to guide future therapy and the promise of combination therapy to further improve the efficacy of checkpoint inhibition.

### Rationale for immune checkpoint blockade in gastroesophageal cancer

Seminal studies by The Cancer Genome Atlas (TCGA) proposed a new framework in gastroesophageal cancer with 4 subtypes in gastric cancer and 3 molecular subtypes in esophageal cancer based on comprehensive genomic profiling (13,14). Notably, Epstein-Barr virus (EBV)-positive subtypes (8.8%) were characterized by PD-L1/PD-L2 amplification and 21.7% of cases demonstrated microsatellite instability (MSI) suggesting that checkpoint inhibition may potentially be a viable approach in gastric cancer.

PD-L1 expression on tumor and immune cells (ICs) infiltrating tumor assessed by immunohistochemistry (IHC) has increasingly been shown to predict for tumor response to PD-1/PD-L1 inhibitors [odds ratio (OR) 2.26; 95% confidence interval (CI), 1.85–2.75, P<0.001] across all tumor types (15). A number of meta-analyses have suggested that PD-L1 expression may represent a poor prognostic marker in gastrointestinal (GI) cancers including gastric cancer (16-23). In an initial large series of GI cancer patients, the rate of PD-L1 expression ≥10% was nearly 50% irrespective of method of IHC evaluation used (17). Although PD-L1 overexpression was seen in as high as 74% of gastric cancers and 78% of esophageal cancers (all stages) in one series, another meta-analysis reported PD-L1 positive rates of 14.32–69.40% in gastric cancer patients (all stages) likely owing to geographic variation, discrepancies in disease characteristics and tumor stage, differences in IHC evaluation method, and variation in cut-off values for positivity or overexpression (19,22). In metastatic gastric cancer patients only, PD-L1 positivity (≥1% expression on tumor/ICs) was observed to be 8.4% on tumor cell (TC) and 65.3% on IC in a prospective cohort analyzed by the 22C3 PharmDx assay (24).

PD-L1 expression alone may not be adequate in predicting response to PD-1/PD-L1 inhibition given a proportion of PD-L1-expressing tumors that fail to respond to therapy (25). MSI status or DNA mismatch repair-deficiency (MMR-D) has been the only other biomarker to define an FDA-approved indication (May 23, 2017) for PD-1 blockade in advanced gastroesophageal cancer (26). In contemporary meta-analyses of gastric cancer patients (across all stages), MSI was identified in 8.5–37.8%, again with heterogeneity likely attributable to disease characteristics and methodology (27-29). The rate of MSI (defined as tumors lacking either MLH1, MSH2, PMS2, or MSH6 expression) in a prospective observational cohort of metastatic gastric cancer patients has been shown to be 6.2% (24). As evidenced in these biomarker analyses, there is growing support the utility of checkpoint inhibition in gastroesophageal cancer.

### Phase I trials

A number of phase I trials have assessed the role of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer (7,30-42) (Table 1). KEYNOTE 012 was a multicenter open-label trial that assessed the toxicity profile and efficacy of pembrolizumab in previously treated gastric cancer with PD-L1 expression (30). Sixty-five of 140 patients (40%) screened positive for PD-L1. In this study, the authors observed 5/13 patients (13%) with grade ≥3 adverse reactions. Overall response rate (ORR) of 22% was driven exclusively by partial responses with median progression-free survival (PFS) 1.9 months (95% CI, 1.8–3.5) and median OS 11.4 months (95% CI, 5.7–not reached). The findings of this study were promising given the improved OS in comparison to single-agent chemotherapy and the lack of unexpected toxicities.

A number of different phase I trials have observed the manageable toxicity profile of a variety of experimental PD-1/PD-L1 inhibitors. In one study, the authors reported that the PD-L1 inhibitor MPDL-3280A achieved an ORR of 18% with 13% of patients experiencing grade ≥3 adverse events most commonly fatigue (31). Of the 141 patients in the study, 18% of the study participants demonstrated PD-L1 expression. The presence of PD-L1 in tumor-infiltrating immune cells may correlate with response to checkpoint inhibition (P=0.007). Preliminary results from the PD-1 inhibitor BGB-A317 have also almost demonstrated promising findings (32). In this open-label phase I study of 55 patients with recurrent or refractory gastroesophageal cancer, the authors did not observe any grade ≥3 adverse events related to treatment. Disease-control rate (DCR) was reported to be 32% with 3 patients reported have
<table>
<thead>
<tr>
<th>n</th>
<th>Primary tumor</th>
<th>Doses</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td>Gastric (KEYNOTE-012)</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks for 2 years or PD</td>
<td>Safety, tolerability, ORR</td>
<td>13% grade ≥3 AEs: grade 3 fatigue (n=2), grade 3 pemphigoid, hypothyroidism, neuropathy (n=1), grade 4 pneumonitis (n=1); ORR 22% (95% CI, 10–39)</td>
<td>(30)</td>
</tr>
<tr>
<td>277</td>
<td>Multiple cancer types</td>
<td>MPDL-3280A 20 mg/kg every 3 weeks</td>
<td>Safety and tolerability</td>
<td>13% grade ≥3 AEs: fatigue (n=5); increased ALT, increased AST, hypoxia (n=1 per AE); asthenia, dyspnea, myalgia, anemia, hyperglycemia, hyponatremia, cardiac tamponade, hypophosphatemia, tumor lysis syndrome (n=2 per AE); nausea, headache, influenza-like illness, pain, vomiting (n=1 per AE); ORR 18% overall; 26% of melanoma, 21% of NSCLC, 13% of RCC, 13% other</td>
<td>(31)</td>
</tr>
<tr>
<td>55</td>
<td>GEA</td>
<td>BGB-A317 at 2 mg/kg or 5 mg/kg every 2 or 3 weeks</td>
<td>Safety, tolerability, and efficacy</td>
<td>46% grade ≥3 AEs however none were treatment related; DCR of 32% with 6% PR</td>
<td>(32)</td>
</tr>
<tr>
<td>151</td>
<td>Multiple cancer types</td>
<td>MEDI4736 10 mg/kg IV every 2 weeks for 12 months</td>
<td>Safety and efficacy</td>
<td>7% grade ≥2 AEs with 13% fatigue, 8% nausea, 6% rash, 5% vomiting, and 5% pyrexia</td>
<td>(33)</td>
</tr>
<tr>
<td>83</td>
<td>Esophageal (KEYNOTE-028)</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until disease progression</td>
<td>Safety and ORR</td>
<td>ORR 30% (95% CI, 13–53%)</td>
<td>(34)</td>
</tr>
<tr>
<td>28</td>
<td>GEA</td>
<td>Ramucirumab 8 mg/kg on days 1 &amp; 8 with pembrolizumab 200 mg on day 1 every 3 weeks</td>
<td>Safety and tolerability</td>
<td>61% grade ≥3 adverse events with 14% hypotension, 11% diarrhea, and 7% liver function abnormalities; DCR 68%; median PFS 5.3 months (95% CI, 3.2–11)</td>
<td>(35)</td>
</tr>
<tr>
<td>29</td>
<td>GEA</td>
<td>Ramucirumab 8 mg/kg and durvalumab 750 mg every 2 weeks</td>
<td>Safety and tolerability</td>
<td>35% grade ≥2 AEs with 34% hypertension, 31% fatigue, 24% headache, 21% diarrhea, 10% pyrexia, and 10% decreased appetite; 5/29 patients (17%) PR; median PFS 2.6 months (95% CI, 1.45–6.28)</td>
<td>(36)</td>
</tr>
<tr>
<td>30</td>
<td>Gastroesophageal</td>
<td>SHR-1210 60 mg with escalations to 200 and 400 mg</td>
<td>Safety, activity, and pharmacokinetics</td>
<td>6.7% grade 3a AEs; 3.3% interstitial lung disease, 3.3% pruritus; ORR 23.3% (95% CI, 9.9–42.3%); median PFS 8.0 weeks (95% CI, 7.9–8.1 weeks)</td>
<td>(37)</td>
</tr>
<tr>
<td>43</td>
<td>GEA, hepatocellular</td>
<td>SHR-1210 200 mg every 2 weeks and apatinib 125–500 mg once daily until unacceptable toxicity or disease progression</td>
<td>Safety and efficacy</td>
<td>60.6% grade ≥3 AE; 15.2% hypertension, 15.2% increased aspartate aminotransferase; ORR 30.8% overall (95% CI, 17.0–47.6%); 5/25 gastroesophageal patients (20%) with PR; median PFS 2.9 months (95% CI, 2.5–4.2 months)</td>
<td>(38)</td>
</tr>
<tr>
<td>57</td>
<td>GEA (JAVELIN)</td>
<td>Avelumab 10 mg/kg every 2 weeks</td>
<td>Safety and efficacy</td>
<td>3/40 patients (7.5%) grade ≥3 AE including alanine aminotransferase increase, anemia, and hyponatremia; ORR 10.0% (95% CI, 2.8–23.7%); median OS 9.1 months (95% CI, 7.2–11.2 months)</td>
<td>(39)</td>
</tr>
</tbody>
</table>
achieved partial response. The PD-1 inhibitor MEDI4736 (durvalumab) has also demonstrated a tolerable side effect profile in the treatment of multiple cancer types including NSCLC, gastrointestinal, hepatocellular carcinoma, melanoma (cutaneous and ocular), pancreatic, SCCHN and triple negative breast cancer with 7% ≥ grade 3 AEs most commonly from fatigue (33). The study is currently ongoing however authors report observing tumor shrinkage across a variety of malignancies. Another study sought to evaluate the safety and efficacy of the anti-PD-1 inhibitor JS001 in 56 Chinese patients with advanced esophageal cancer (42). PD-L1 positively was 21.4%. ORR was 23.5% with 8 partial responses. No grade 3 ≥ AEs were observed. The authors did not observe any difference in clinical response in patients with or without PD-L1 expression.

**KEYNOTE 028** evaluated the safety and efficacy of pembrolizumab in 83 patients with esophageal malignancy (34). Thirty-seven of the cohort (45%) demonstrated PD-L1-positive tumors. ORR was 30% (95% CI, 13–53%) with PFS of 30% and 22% at 6 and 12 months, respectively. Median duration of response was 40 weeks.

<table>
<thead>
<tr>
<th>n</th>
<th>Primary tumor</th>
<th>Doses</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>150</td>
<td>GEA (JAVELIN)</td>
<td>Avelumab 10 mg/kg every 2 weeks</td>
<td>Safety and efficacy</td>
<td>8.7% grade ≥3 AE with 1 treatment-related death (hepatic failure/autoimmune hepatitis); 1st line cohort: ORR 6.7% (95% CI 2.5–13.9) with CR 2.2%; 2nd line cohort: ORR 6.7% (95% CI, 1.8–16.2), DCR 28.3%, median PFS 1.4 months (95% CI, 1.3–1.5), median OS 6.8 months (95% CI, 5.4–9.5)</td>
<td>(40)</td>
</tr>
<tr>
<td>92</td>
<td>GEA</td>
<td>Pembrolizumab 200mg day 1 every 3 weeks with ramucirumab 10 mg/kg on day 1 or 8 mg/kg days 1 and 8 every 3 weeks</td>
<td>Safety and efficacy</td>
<td>ORR and OS in PD-L1 positive vs. negative patients (9% vs. 6%, 14.9 vs. 5.2 months)</td>
<td>(41)</td>
</tr>
<tr>
<td>56</td>
<td>Esophageal</td>
<td>JS001 3 mg/kg every 2 weeks</td>
<td>Safety and efficacy</td>
<td>No grade ≥3 AE; ORR 23.5% with 8 PR</td>
<td>(42)</td>
</tr>
<tr>
<td>16</td>
<td>GEA</td>
<td>Induction nivolumab every 2 weeks prior to carboplatin + paclitaxel/radiation plus 3 additional cycles of nivolumab on weeks 1, 3 and 5 of chemoradiation followed by Ivor-Lewis esophagectomy</td>
<td>Safety and feasibility</td>
<td>Grade ≥3 AEs include dermatitis (1/16) and hepatitis (1/16); pathological complete response 40%</td>
<td>(43)</td>
</tr>
<tr>
<td>6</td>
<td>Esophageal</td>
<td>Durvalumab 1.5 g + Tremelimumab 75 mg on day 1 every 4 weeks plus chemotherapy</td>
<td>Safety and tolerability</td>
<td>3/6 patients with grade ≥3 neutropenia attributed to chemotherapy; 2/6 patients with PR</td>
<td>(44)</td>
</tr>
<tr>
<td>18</td>
<td>Gastric</td>
<td>Cohort 1 (n=8): Andecaliximab (GS-5745) 800 mg IV every 2 weeks; Cohort 4 (n=10): Nivolumab plus Andecaliximab</td>
<td>Safety and tolerability, pharmacokinetics</td>
<td>Cohort 1: Grade ≥ 3 AEs with anemia (25%), fatigue (13%), hydronephrosis (13%); Cohort 4: Grade ≥3 AEs were anemia (20%), DIC (10%), fatigue (10%), anorexia (10%); ORR 40%</td>
<td>(45)</td>
</tr>
<tr>
<td>23</td>
<td>GEA</td>
<td>GLS-010 (anti-PD-1) 240 mg every 2 weeks</td>
<td>Efficacy</td>
<td>4 patients with PR; Grade ≥3 AEs include multiple organ dysfunction (n=1), interstitial lung disease (n=1), increased bilirubin (n=1)</td>
<td>(46)</td>
</tr>
</tbody>
</table>

GEA, gastroesophageal adenocarcinoma; PD, progressive disease; ORR, overall response rate; CI, confidence interval; AE, adverse event; DCR, disease-control rate; CR, complete response; PR, partial response.
Recently, there has also been a strong interest in combination therapy with PD-1/PD-L1 inhibition. In a phase I study, the authors evaluated the safety and tolerability of ramucirumab (anti-VEGFR-2) plus pembrolizumab in patients with gastroesophageal malignancy (35). Twenty-eight patients were enrolled in this study; 68% were PD-L1 positive. Seventeen patients (61%) experienced grade ≥3 adverse events most commonly hypertension (14%). Disease control rate was 68% while median PFS was 5.3 months. Another phase I study evaluated the safety and tolerability of ramucirumab plus durvalumab in 29 patients with gastroesophageal malignancy (36). Forty-eight percent had PD-L1 ≥25% expression. Thirty-five percent of patients experienced grade ≥3 treatment-related AEs with most common AEs including hypertension, fatigue, headache, diarrhea, pyrexia, and decreased appetite. Five patients (17%) achieved confirmed partial response; median PFS was 2.6 months. In another study, the authors evaluated the safety and tolerability of ramucirumab with pembrolizumab in 92 patients with advanced gastroesophageal cancer (41). ORR and OS in PD-L1 positive versus PD-L1 negative patients were 9% and 14.9 months compared to 6% and 5.2 months, respectively. From the results of the study, it appears that combination therapy may provide greater benefit to patients with PD-L1 positive cancers compared with PD-L1 negative patients.

A phase I study from China evaluated the evaluated the safety and efficacy of SHR-1210 in 30 patients with advanced gastroesophageal cancer. Of the 28 Chinese patients who had PD-L1 status evaluated, 13 patients (46.4%) had PD-L1-positive tumors. Two patients with grade 3 treatment-related AEs with one patient with grade 5 interstitial lung disease. ORR was 7/30 patients (23.3%) (95% CI, 9.9–42.3%) with one patient with complete response and 6 patients with partial responses. ORR in PD-L1—positive tumors [3 of 13 (23.1%)] which was similar to patients with PD-L1—negative tumors [4 of 15 (26.7%); P=1.000]. Median was PFS 8.0 weeks (95% CI, 7.9–8.1 weeks). Combination strategies utilizing SHR-1210 are also being studied. In one study, the authors assessed the safety and SHR-1210 (anti-PD-1 antibody) and apanitib (VEGFR2 inhibitor) in 43 patients with gastroesophageal and hepatocellular cancer (38). Twenty out of thirty-three patients (60.6%) who achieved recommended phase II dose (RP2D) experienced a grade ≥3 treatment-related adverse event most commonly hypertension (15%) or liver function abnormalities (15%). ORR observed was 30.8% (95% CI, 17.0–47.6%); 5/25 gastroesophageal patients achieved partial responses.

Avelumab is a PD-L1 inhibitor of clinical interest that has been studied in a number of trials. In the Japanese JAVELIN phase I trial, the authors evaluated the safety and efficacy of avelumab in 151 Japanese patients with advanced gastroesophageal cancer (39). PD-L1 expression was not assessed in this study. Three out of forty patients experienced (7.5%) grade 3 AE including anemia, alanine aminotransferase increase, and hyponatremia. The ORR was 10.0% (95% CI, 2.8–23.7%) while median OS was 9.1 months (95% CI, 7.2–11.2 months). In another JAVELIN study, the authors evaluated the role of avelumab in 150 patients with advanced gastroesophageal cancer without or with disease progression after first line therapy (1L and 2L cohort, respectively) (40). Eight point seven percent of all patients experienced grade ≥3 AE with 1 treatment-related death secondary to hepatic failure/autoimmune hepatitis. In the 1L cohort, ORR was 6.7% (95% CI, 2.5–13.9) with a complete response of 2.2%. In the 2L cohort, ORR was 6.7% (95% CI, 1.8–16.2), DCR 28.3%, median PFS 1.4 months (95% CI, 1.3–1.5), and median OS 6.8 months (95% CI, 5.4–9.5).

**Phase II trials**

Several phase II clinical trials have studied the efficacy of PD-1/PD-L1 blockade in advanced gastroesophageal cancers (Table 2). CheckMate 032 was a phase I/II study that studied the clinical impact of nivolumab, an anti-PD-1 monoclonal antibody, along with ipilimumab, a CTLA-4 inhibitor in 160 patients with advanced gastroesophageal malignancy (47). Patients were randomized to one of three cohorts: nivolumab alone, nivolumab 1 mg/kg with ipilimumab 3 mg/kg (N1+I3), or nivolumab 3 mg/kg with ipilimumab 1 mg/kg (N3+I1). Thirty-nine out of 127 evaluable patients (31%) demonstrated PD-L1 positivity (≥1%). In general, the ORRs were greater in cancers with PD-L1 expression (nivolumab alone 19%, N1+I3 40%, N3+I1 23%) however there remain a modest response in PD-L1 deficient malignancies as well (12% nivolumab alone, 22% N1+I3, 0% N3+I1). In addition, PD-L1 expression appears to be correlated with improved 12-month OS in the N1+I3 cohort (50%) compared to nivolumab alone (34%) and N3+I1 (23%) cohorts. However, the small sample size of PD-L1 positive cancers in each cohort makes it difficult draw definitive conclusions about whether PD-L1 status alone may predict who will benefit from checkpoint
<table>
<thead>
<tr>
<th>n (phase)</th>
<th>Experimental arm</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I/II, n=160 (CheckMate 032)</td>
<td>N1 + I3: Nivolumab (N) 1 mg/kg every 2 weeks and ipilimumab (I) 3 mg/kg every 3 weeks; N3+I1: Nivolumab 3 mg/kg and ipilimumab 1 mg/kg every 3 weeks</td>
<td>N3: Nivolumab 3 mg/kg every 2 weeks</td>
<td>ORR</td>
<td>N3: ORR 12% overall; PD-L1 ≥1%, ORR 19%; PD-L1&lt;1% ORR 12%</td>
<td>(47)</td>
</tr>
<tr>
<td>Phase II, n=259 (KEYNOTE-059)</td>
<td>Cohort 1: Pembrolizumab 200 mg every 3 weeks up to 2 years</td>
<td>N/A</td>
<td>ORR, safety, tolerability</td>
<td>Cohort 1: Grade 3≥ AE 17.8% with 2 treatment-related deaths; ORR 11.6% overall (95% CI, 8.0–16.1) with CR 2.3% (95% CI, 0.9–5.0)</td>
<td>(48-50)</td>
</tr>
<tr>
<td></td>
<td>Cohort 2 (1st line): Pembrolizumab 200 mg every 3 weeks up to 2 years + cisplatin (80 mg/m² day 1), + 5-FU (800 mg/m² days 1–5 every 3 weeks) or capecitabine (Japan only, 1,000 mg/m² BID)</td>
<td></td>
<td></td>
<td>Cohort 2: Grade 3≥ AE 76% with discontinuation of treatment in 3 patients (12%); ORR 60% (95% CI, 39–79) overall; PD-L1+ 73% (95% CI, 45–92); PD-L1– 38% (95% CI, 9–76); median PFS 7 months (95% CI, 6–11); median OS 14 months (95% CI, 9–not reached)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cohort 3 (1st line, PD-L1+): Pembrolizumab 200 mg every 3 weeks up to 2 years</td>
<td></td>
<td></td>
<td>Cohort 3: Grade 3≥ AE 22.6% with 1 treatment-related death (pneumonitis); ORR 25.8% (95% CI, 11.9–44.6); median PFS 3.3 months (95% CI, 2.0–6.0)</td>
<td></td>
</tr>
<tr>
<td>Phase II, n=29</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks</td>
<td>N/A</td>
<td>ORR, PFS</td>
<td>ORR 48% (95% CI, 29–67%); Median PFS not reached</td>
<td>(51)</td>
</tr>
<tr>
<td>Phase II, n=52</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks</td>
<td>N/A</td>
<td>ORR, PFS</td>
<td>MMR-deficient: ORR 50% (95% CI, 31–69%); Median PFS not reached; MMR-proficient: ORR 0% 95% CI (0–14%); Median PFS</td>
<td>(52)</td>
</tr>
<tr>
<td>Phase II, n=41 (KEYNOTE-016)</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks</td>
<td>N/A</td>
<td>ORR, PFS</td>
<td>MMR-deficient CRC: ORR 40%, PFS 78%; Median PFS and OS not reached</td>
<td>(53)</td>
</tr>
<tr>
<td></td>
<td>Cohort A: Mismatch repair (MMR)-deficient colorectal cancers (CRC)</td>
<td></td>
<td></td>
<td>MMR-proficient CRC: ORR 0%, PFS 11%; Median PFS 2.2 months, OS 5.0 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cohort B: MMR-proficient CRC</td>
<td></td>
<td></td>
<td>MMR-deficient non-CRC: ORR 71%, PFS 67%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cohort C: MMR-deficient non-CRC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II, n=86</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks</td>
<td>N/A</td>
<td>ORR</td>
<td>ORR 53% (95% CI, 42–64%) overall with 21% CR</td>
<td>(54)</td>
</tr>
</tbody>
</table>

Table 2 (continued)
<table>
<thead>
<tr>
<th>n (phase)</th>
<th>Experimental arm</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II, n=65</td>
<td>Nivolumab 3 mg/kg once every 2 weeks in 6-week cycles</td>
<td>N/A</td>
<td>ORR</td>
<td>ORR 17% (95% CI, 10–28)</td>
<td>(55)</td>
</tr>
<tr>
<td>Phase II, n=35</td>
<td>Pembrolizumab 200 mg, Trastuzumab 6 mg/kg (after 8 mg/kg load), Oxaliplatin 130 mg/m² every 3 weeks, Capecitabine 850 mg/m²² 2 weeks on/1 week off (or 5-FU continuous infusion)</td>
<td>N/A</td>
<td>6-month PFS</td>
<td>ORR 83% (95% CI, 63–95%) with 17 PR and 3 CRs; median PFS 11.4 (95% CI, 6–15) months</td>
<td>(56)</td>
</tr>
<tr>
<td>Phase II, n=24</td>
<td>Durvalumab 1,500 mg IV every 4 weeks for up to 1 year after surgery</td>
<td>N/A</td>
<td>1-year RFS</td>
<td>1-year and projected 26-month RFS are 78.6% and 62.9%, respectively</td>
<td>(57)</td>
</tr>
<tr>
<td>Phase II, n=40</td>
<td>Gastric</td>
<td>Olaparib 300 mg PO BID followed by olaparib and durvalumab (1.5 g every 4 weeks)</td>
<td>Disease-control rate, safety, feasibility</td>
<td>Grade ≥3 AEs with 19/40 with grade 3 and 3/40 with grade 4 AE; Most common AE include lipase increase, anemia, fatigue, dysphagia; ORR 10% with 2 patients with CR; median duration of response 11.1 months; disease-control rate at 12 weeks 26%</td>
<td>(58)</td>
</tr>
<tr>
<td>Phase II, n=121 (KEYNOTE-180)</td>
<td>Pembrolizumab 200 mg every 3 weeks</td>
<td>N/A</td>
<td>ORR</td>
<td>Overall ORR 9.9% (95% CI, 5.2–16.7%); PD-L1-positive tumors: ORR 13.8% (95% CI, 6.1–25.4%); PD-L1-negative tumors: ORR 3% (95% CI, 1.8–15.5%); 4.1% grade ≥3 AE</td>
<td>(59)</td>
</tr>
<tr>
<td>Phase I/II, n=66</td>
<td>Margretuximab 15 mg/kg and pembrolizumab 200 mg every 3 weeks</td>
<td>N/A</td>
<td>Safety, ORR, median OS and PFS, DCR</td>
<td>12/66 patients (18.2%) grade ≥3 AE; ORR 12/29 patients (41.4%; 95% CI, 23.5–61.1); DCR 21/29 patients (72.4%; 95% CI, 52.8–87.3); median PFS 5.5 months (95% CI, 2.3–7.6); median OS not reached</td>
<td>(60)</td>
</tr>
<tr>
<td>Phase II, n=46</td>
<td>Nivolumab (3 mg/kg every 2 weeks) and ramucirumab (8 mg/kg, every 2 weeks)</td>
<td>N/A</td>
<td>6-month PFS, safety</td>
<td>6-month PFS 37.4% (95% CI, 25.7–49.2%)</td>
<td>(61)</td>
</tr>
<tr>
<td>Phase III, n=493 (ATTRACTION-02)</td>
<td>Nivolumab 3 mg/kg every 2 weeks</td>
<td>Placebo</td>
<td>OS</td>
<td>Nivolumab: median OS 5.32 months, 6-month OS 46.4%, 12-month OS 26.6%, ORR 11.2%, median PFS 1.61 months</td>
<td>(62)</td>
</tr>
</tbody>
</table>

Placebo: median OS 4.14 months, 6-month OS 34.7%, 12-month OS 10.9%, ORR 0%, median PFS 1.45 months |
Table 2 (continued)

<table>
<thead>
<tr>
<th>n (phase)</th>
<th>Experimental arm</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase III, n=592  (KEYNOTE-061)</td>
<td>Pembrolizumab 200 mg every 3 weeks for up to 2 years</td>
<td>Paclitaxel 80 mg/m² intravenously on days 1, 8, and 15 of 4-week cycles</td>
<td>OS, PFS</td>
<td>Experimental arm: median OS 9.1 months (95% CI, 6.2–10.7); median PFS 1.5 months (95% CI, 1.4–2.0)</td>
<td>(63)</td>
</tr>
<tr>
<td>Phase III, n=628  (KEYNOTE-181)</td>
<td>Pembrolizumab 200 mg every 3 weeks for up to 2 years</td>
<td>Docetaxel (75 mg/m² on day 1 of each 21-day cycle), Paclitaxel (80 to 100 mg/m² on days 1, 8, and 15 of each 28-day cycle) or irinotecan (80 mg/m² on day 1 of each 14-day cycle)</td>
<td>OS</td>
<td>Median OS in PD-L1 CPS ≥10 (9.3 vs. 6.7 months; HR 0.69; 95% CI, 0.52–0.93; P=0.0074); 12-month OS rate in CPS ≥10 43% vs. 20%</td>
<td>(64)</td>
</tr>
<tr>
<td>Phase III, n=371  (JAVELIN Gastric 300)</td>
<td>Avelumab 10 mg/kg IV every 2 weeks</td>
<td>Physician choice chemo, paclitaxel 80 mg/m² days 1, 8, 15, or irinotecan 150 mg/m² IV days 1, 15 of a 28-day cycle</td>
<td>OS</td>
<td>Experimental arm: median OS 4.6 months (95% CI, 3.6–5.7); median PFS 1.4 months (95% CI, 1.4–1.5)</td>
<td>(65)</td>
</tr>
</tbody>
</table>

PD, progressive disease; ORR, overall response rate; CI, confidence interval; MMR, mismatch repair; CPS, combined positive score; RFS, relapse-free survival; GEJ, gastroesophageal junction; DCR, disease-control rate.
inhibition.

KEYNOTE 059 was a seminal study that paved the way for FDA approval of pembrolizumab in refractory gastroesophageal cancer with PD-L1 expression on September 22, 2017 (48-50). This open-label, multicenter clinical study of 259 patients with gastroesophageal malignancy and evidence of disease progression despite prior therapy. Patients were enrolled into 3 cohorts: pembrolizumab for patients who previously received two lines of therapy (cohort 1), pembrolizumab with cisplatin and either 5-fluorouracil or capecitabine (cohort 2), and pembrolizumab for patients with PD-L1 positivity (21%) (cohort 3). Within cohort 1, the authors reported that patients with PD-L1 expression (148/259, 57.1%) had an ORR 15.5% (95% CI, 10.1–22.4%) in comparison to 6.4% (95% CI, 2.6–12.8%) in PD-L1 negative tumors (109/259, 42.1%), which suggests that PD-L1 negative status did not preclude observing a response to therapy. Of the 259 patients enrolled, 7 patients or 4% of the cohort were found to be MSI-high. Four out of seven patients (57.1%) demonstrated an objective response (95% CI, 18.4–90.1%). In contrast, patients with non-MSI-high malignancies had an ORR of 9.0%. While MSI-high tumors demonstrated a robust response, the sample size was small and most of the responses within the study were amongst non-MSI high patients.

Preliminary results from cohort 2 and 3 are also available (48,49). Cohort 2 reported on 25 patients who received first-line chemotherapy in addition to pembrolizumab. The authors observed an ORR of 60% overall with an ORR in PD-L1+ of 73% (95% CI, 45–92) while achieving an ORR of PD-L1− 38% (95% CI, 9–76) PD-L1− tumors. These results suggest that PD-L1 status may identify individuals who may benefit from PD-L1 inhibition, however the sample size in the study population is too small to draw any definitive conclusions. Cohort 3 enrolled 31 patients to receive pembrolizumab as first-line therapy with PD-L1 positivity. The authors observed an ORR of 25.8% (95% CI, 11.9–44.6) with complete response in 3.2% of patients. Median PFS 3.3 months (95% CI, 2.0–6.0). Seven patients (22.6%) experienced grade ≥3 adverse events; one patient had a treatment-related death from pneumonitis. Overall, these preliminary results demonstrate promising activity and a manageable toxicity profile of pembrolizumab in patients with PD-L1 positive gastroesophageal tumors.

There have also been studies to study the clinical impact of PD-1 inhibition in the setting of mismatch repair deficiency. It has been hypothesized that the burden of immunogenic antigens from mismatch repair deficits may favor the use of checkpoint inhibition to mobilize the immune system against cancer cells. In a phase II study of 29 patients with cancers of multiple types including gastric malignancy, the authors observed an ORR of ORR 48% (95% CI, 29–67%) (51). Median PFS was not reached. The results of these studies ultimately led to the tissue-agnostic approval of pembrolizumab in treatment-refractory malignancies. Another phase II trial assessed the impact of pembrolizumab in 52 patients with or without mismatch repair deficiency (MMR) in colon cancers (52). In tumors with MMR-deficient, ORR was 50% (95% CI, 31–69%) while tumors with MMR-proficient had an ORR 0% (95% CI, 0–14%). In a phase II study (KEYNOTE-016) assessing the clinical impact of pembrolizumab in patients with colorectal cancer with or without MMR deficiency, the authors observed an ORR of 40% and 0%, respectively. In addition, the authors included a third cohort of non-colorectal MMR-deficient tumors, which demonstrated an ORR of 71%. The study was further expanded to include 86 patients with multiple cancer types with MMR-deficiency (54) and found to have an ORR of 53% (95% CI, 42–64%) along with a CR rate of 21%. Within this study, 5 patients had gastroesophageal cancer and had a CR rate of 60%. The promising results from this study along with results from KEYNOTE-012, -164, -028, and -158 contributed to the accelerated approval of pembrolizumab on May 23, 2017 for treatment of microsatellite instability-high (MSI-H) malignancies. Other studies including other PD-1 inhibitors are listed in the Table 2 (55).

A recent phase II clinical study with 35 patients with previously untreated metastatic HER2-positive gastroesophageal tumors with pembrolizumab and trastuzumab along with chemotherapy with the primary endpoint of evaluating 6-month PFS (56). Fourteen patients enrolled had cancer in the esophagus, 12 in the gastroesophageal junction, and 9 with gastric. PD-1 expression status was positive in 14 patients; no tumors demonstrated MSI. ORR was 83% (95% CI, 63–95%) with 17 partial responses and 3 complete responses. Median PFS was 11.4 months (95% CI, 6–15). In addition, patients in the study tolerated the regimen; common grade ≥3 adverse effects include decreased lymphocyte count (12%). Overall, this study suggests potential synergy for this combination regimen in gastroesophageal tumors and represents a significant improvement compared to the response rate of frontline trastuzumab plus 5-FU/platinum chemotherapy.
In subgroup analysis, it did not appear that PD-L1 status conferred an advantage in OS or PFS. An ongoing phase III trial (KEYNOTE-811; NCT03615326) utilizing this combination for frontline therapy will help to clarify the impact on OS.

The Big Ten investigators recently presented the results demonstrating the safety and efficacy of durvalumab in patients with locally advanced gastroesophageal cancer in a phase II trial (57). The trial enrolled 24 patients with gastroesophageal cancer; 14 patients had gastroesophageal junction adenocarcinoma while 10 had distal esophageal adenocarcinoma. The 1-year and projected relapse-free survival were 78.6% and 62.9%, respectively. In addition, the treatment was well-tolerated with 5/18 patients (20.8%) experiencing grade ≥3 adverse events, most commonly diarrhea, hepatitis, hypoglycemia, and encephalopathy. A recent phase II study of 40 patients with relapsed gastric cancer was administered the PARP inhibitor olaparib followed by combination olaparib and durvalumab to evaluate the DCR, safety, and tolerability (58). The authors reported the regimen was tolerated with 22/40 patients (55%) experiencing grade ≥3 adverse reactions most commonly anemia, fatigue, dysphagia, and hyponatremia. The ORR was 10% with 2 complete and partial responses observed. Median duration of response to therapy was 11.1 months with 12-week DCR 26%. Because the responses occurred during combination therapy, there may potentially be synergistic effects between the two therapies.

KEYNOTE 180 was a phase II study of 121 patients with advanced, metastatic esophageal cancer to evaluate the efficacy and toxicity profile pembrolizumab (59). Of the 121 patients, 48 (47.9%) had tumors positive for PD-L1. Overall ORR was 9.9% (95% CI, 5.2–16.7%), 13.8% (95% CI, 6.1–25.4%) amongst PD-L1-positive tumors, and 6.3% (95% CI, 1.8–15.5%) from PD-L1-negative tumors (4 of 63). The regimen was well tolerated with 12.4% experiencing a grade ≥3 adverse events. Only one treatment-related death from pneumonitis was observed. Other studies that were recently presented at ASCO GI are listed in Table 1 (60,61).

### Phase III trials

Several phase III trials have studied the clinical impact of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancers (Table 2). In a randomized, double-blind, placebo-controlled phase III trial (ATTRACTION-02), 493 patients from Japan, South Korea, and Taiwan with refractory gastroesophageal cancer were randomized (2:1) to receive either nivolumab 3 mg/kg or placebo with the primary endpoint of evaluating OS. Twenty-six patients (14%) were found to be PD-L1 positive (62). In comparison to the placebo cohort, the experimental arm had improved median OS of 5.26 months (95% CI, 4.60–6.37) compared to 4.14 months (95% CI, 3.42–4.86). In addition, 12-month OS rates were 26.2% (95% CI, 20.7–32.0) in the experimental arm compared with 10.9% (95% CI, 6.2–17.0) in the placebo cohort. There were 5 patients with treatment-related deaths. In an exploratory analysis, PD-L1 tumor status did not appear to significantly impact OS. The median OS in tumors with PD-L1 positivity in experimental vs. placebo arm was 5.22 months (95% CI, 2.79–9.36) vs. 3.83 (95% CI, 0.79–9.36) in comparison to PD-L1 negative tumors with median OS of 6.05 months (95% CI, 4.83–8.54) vs. 4.19 months (95% CI, 3.02–6.93). Given the small sample size, it is difficult to conclude how PD-L1 status may impact the choice of therapy. The results of this study led to the approval of pembrolizumab in Japan for use as third-line therapy in advanced gastroesophageal cancer.

KEYNOTE-061 was a multicenter phase III trial enrolled 592 patients with refractory, PD-L1 positive gastroesophageal cancer to receive either pembrolizumab 200 mg every 3 weeks for up to 2 years or standard-dose paclitaxel (63). Three hundred ninety-five out of 592 patients (66.7%) were found to be PD-L1 positive. Median OS was 9.1 months (95% CI, 6.2–10.7) while Median PFS 1.5 months (95% CI, 1.4–2.0) in experimental arm while median OS and PFS were 8.3 months (95% CI, 7.6–11 months) (95% CI, 3.1–4.2), respectively in control arm. Forty-two out of 294 patients (14%) experienced grade ≥3 adverse events in experimental arm compared to 96/276 patients (35%) in control arm. Response rate were similar with 16% (95% CI, 11–22%) in experimental arm compared to 14% (95% CI, 9–19%) in control arm. While pembrolizumab appeared to have a more manageable toxicity profile than paclitaxel, it did not appear to significantly improve OS. In subgroup analyses, the authors did observe improved response rates in patients with increased PD-L1 combined positive scores (CPS) ≥10 (24.5% vs. 9.1%) and MSI-H tumors irrespective of PD-L1 CPS score (46.7% vs. 16.7%). As such, there may be potential role for MSI status and PD-L1 expression in identifying patients who may benefit from checkpoint inhibition.

KEYNOTE-181 was a randomized, phase III study that
demonstrated significantly improved OS in pembrolizumab as second-line therapy compared to chemotherapy in a study of 628 patients with advanced esophageal cancers with PD-L1 expression (64). Both patients with squamous cell or adenocarcinoma histologies were recruited including Siewert I adenocarcinomas of the GE junction. Of the 628 patients enrolled, 222 patients had PD-L1 CPS ≥10. In patients with CPS ≥10, the median OS was 9.3 vs. 6.7 months (HR 0.69; 95% CI, 0.52–0.93; P=0.0074) and 12-month OS rate was 43% vs. 20%. Statistical significance was not reached for OS in the study amongst patients with squamous cell carcinoma (SCC), however there was still an improvement in OS for patients with SCC (HR 0.78; 95% CI, 0.63–0.96). In addition, pembrolizumab was well-tolerated. These findings support the use of pembrolizumab as potentially a new standard of care for second-line therapy in esophageal cancers.

**Discussion**

Immune checkpoint inhibitors have made great strides in becoming implemented as standard of care options in refractory gastroesophageal cancers. Currently PD-1 inhibitors are approved for use as third-line therapy for PD-L1 positive gastroesophageal cancer (12) and in treatment-refractory metastatic gastroesophageal cancers that are MSI-H (26). As the number of trials investigating checkpoint blockade in gastroesophageal cancer grows (Tables 1,2), it is important to validate predictive biomarkers that will identify patients who will benefit from immunotherapy in gastroesophageal cancer treatment. MSI-H and PD-L1 are probably the earliest and most described predictive biomarkers. A recent prospective study observed that PD-L1 expression was commonly observed in patients with KRAS mutation (P=0.002), PIK3CA mutation (P=0.020), MMR-deficiency (P<0.001) while PD-L1 expression on immune cells were associated with EBV (P=0.034) (24). These findings support screening gastroesophageal tumors for MMR-deficiency and EBV status along with PD-L1 expression.

However, MSI-H and PD-L1+ gastroesophageal tumors still comprise only a fraction of the overall population of gastroesophageal cancer patients in need of further investigation to identify patients who will benefit from immunotherapy. Recent efforts are beginning to explore other predictive biomarkers to predict response to checkpoint blockade in gastroesophageal cancer (66-72). Given the varied outcomes from patients with similar staging in gastric cancer, the 5-factor immunoscore was developed in a retrospective study of 879 patients using IHC to develop a prediction model for enhance prognosis and survival (66). The score includes the assessment of 5 immune features: CD3 invasive margin (IM), CD3 center of tumor (CT), CD8IM, CD45ROCT, and CD66bIM. Higher scores correlated with better 5-year OS and disease-free survival. In addition, the combination of CT and IM along with TNM appeared to provide better prognostic information than TNM staging alone with higher scores correlated with better 5-year OS and disease-free survival. This study also demonstrated that patients with higher immunoscores may benefit from adjuvant therapy in patients with stage II/III gastric cancer. Additional studies have identified that the combination of PD-L1 expression and immunoscore can provide prognostic information (67). Specifically, patients with PD-L1 positive expression demonstrated better prognosis with higher immunoscores than with lower scores. In addition, the combined PD-L1 status and immunoscore was an independent prognostic marker for OS in patients with MSI-H gastric cancer. Other prediction models have been developed including the four-factor immunoscores devised based on hazard ratios on the basis of PD-L1+ immune cells (IC), PD-L1+ TC, PD-1hi, and CD8IMore (68). This scoring system allows for patients to be stratified to low, medium, and high-risk groups with different survival outcomes.

Other biomarkers under investigation include tumor-infiltrating lymphocytes (TILs). In one study of 398 patients, the authors observed that increased TIL density was correlated with reduced risk of disease progression and may be associated with a survival benefit (69). In addition, the study also found that PD-L1 expression and EBV+ was associated with increased TIL density. In addition, MSI has also been correlated with PD-L1 expression and high TILs (71). In addition to immunoscores, other prediction models are currently being studied including the host-immune response index (HIERI). A recent validation study performed gene sequencing to identify 29 immune genes of interest within gastric cancer to stratify patients into 3 groups with prognostic significance (70). The first cluster which was defined by elevated PD-L1 expression, EBV positivity, MSI, and increased TIL density demonstrated the best prognosis while the cluster defined by EBV negativity, microsatellite stability, and low TIL density had poorer outcomes. Of note, half of the immune-active cluster was EBV negative and microsatellite stable suggesting a
Segment of this population may potentially candidates to checkpoint inhibition. T-cell inflamed gene expression profile (GEP) is another molecular biomarker that may predict response to PD-L1 therapy (72). In a study of 574 gastric tumors, an 18-gene signature was measured from extracted tumor RNA; high GEP was associated with tumor grade and clinical stage (P<0.0001). In addition, GEP was associated with improved OS (HR 0.46; 95% CI, 0.32–0.66) and weakly correlated with PD-L1 expression [Spearman r=0.24 (P<0.0001)]. Further investigation will be necessary to validate GEP as a potential biomarker to predict response to immunotherapy.

A recent study provides important insights to the potential role for circulating tumor DNA (ctDNA) and other molecular markers in predicting response to treatment with pembrolizumab (73). In this prospective phase II trial, 61 patients with metastatic gastric cancer who received pembrolizumab demonstrated favorable responses particularly in patients with EBV and MSI-H tumors with ORR of 85.7% and 100%, respectively. In addition, PD-L1 expression was associated with improved response to therapy with ORR of 50% compared to 0% in PD-L1 negative tumors (P<0.001). Furthermore, ctDNA levels correlated well to radiographic response and in posthoc analysis may also predict PFS and risk for disease progression. With increasing use of checkpoint inhibitors in gastroesophageal cancer and in other malignancies, in general, the American Society of Clinical Oncology (ASCO) and Society for Immunotherapy of Cancer (SITC) recently presented recommendations for IO trial reporting standard (74). The report highlighted 12 key recommendations: (I) reporting the criteria to evaluate for response to therapy; (II) including spider or swimmer plots to evaluate response to therapy; (III) defining disease control rates; (IV) criteria to treat patients beyond disease progression; (V) reporting number of patients treated beyond disease progression and significant clinical events including new toxicity and efficacy; (VI) Kaplan-Meier analyses for PFS and OS; (VII) reporting the clinical diagnoses of the toxicity and its symptomatology (VIII) defining the different types of adverse events (i.e., immune-related adverse events) and why they were selected for reporting; (IX) reporting toxicity by grade; (X) reporting interventions to manage toxicity; (XI) reporting acuity and duration of toxicity; and (XII) discussing the rationale for selection of the dose and sequence for treatment regimens. Lastly, while we continue our search for markers to select optimal candidates for checkpoint inhibitor in advanced gastroesophageal cancer, development of novel strategies combining checkpoint blockade with other treatment modalities are being explored to enhance on the efficacy of single-agent checkpoint inhibitors in this setting. Chemotherapy and checkpoint blockade combinations represent an intuitive combination strategy, for example, in gastroesophageal cancer given that cytotoxic therapies have been a foundation for metastatic GEJ treatment for decades.

Chemotherapy has potentially multiple immunologic effects ranging from eliminating immunosuppressive cells such as regulatory T cells or macrophages to enhancing the ability of T cells to detect tumor antigens. Recent findings from Wanderley et al. observed that paclitaxel may act as a TLR4 agonist to modulate and reprogram tumor-associated macrophages towards a M-1 phenotype and thereby potentially improve the efficacy of checkpoint inhibition (75). While these findings lay the groundwork for combination therapy, further studies will help to elucidate the mechanisms that underlie the immunomodulation of chemotherapeutic agents to optimize their potent effects with checkpoint inhibition. A number of studies have sought to evaluate the efficacy of checkpoint inhibitors in combination with chemotherapeutic agents or radiotherapy (43,76-78). One phase II trial found the PD-L1 inhibitor LY3300054 (LY) alone or in combination with ramucirumab or merestinib in 38 patients with advanced, refractory solid tumors demonstrated antitumor activity with one partial response in each cohort (76). Another phase II trial evaluated SHR-1220 with radiotherapy in 20 patients with newly diagnosed locally advanced esophageal SCC intolerable or refused chemoradiotherapy and observed 2 patients (11.1%) with complete responses and 13 patients (72.2%) with partial responses (77). Other studies demonstrating encouraging results include the combination of DKN-01, a monoclonal antibody against DKK1, a potential NK-cell mediator and pembrolizumab (78). Early reporting from 13 patients with advanced gastroesophageal adenocarcinomas, the authors observed that there was 1 partial response amongst 9 evaluable patients. In addition, patients who traditionally were associated with poor response to PD-L1 inhibition (KRAS amplification, PD-L1 negativity, and MSS) demonstrated a potential clinical benefit when utilizing this combination of therapy.

**Conclusions**

The overwhelming evidence clearly supports a role for immunotherapy in gastric and esophageal cancers...
though many unanswered questions remain. The optimal placement of immunotherapy (neoadjuvant, perioperative, maintenance, front line metastatic, all lines, etc.) in the continuum of care continues to evolve and we await important findings from several ongoing phase III trials. Early data has also suggested that immunotherapy activity may be improved via combinations with chemotherapy, other immune targeting agents, trastuzumab, and agents acting on angiogenic pathways. Harmonization among trial reporting and better baseline and longitudinal molecular assessments will aid in refining the optimal patient selection and may one day identify subsets who may only need single agent versus those who may require combination therapies. We have attempted to provide a comprehensive report on available prospective datasets and eagerly await future data.

Acknowledgments

SJ Klempner is supported by the Howard H. Hall fund for esophagogastric cancer research.

Footnote

Conflicts of Interest: J Chao has received research support (institutional), consulting, and speaker fees from Merck and consulting fees from Lilly. SJ Klempner has received speaker fees from Merck and consulting fees from Lilly, Boston Biomedical, Astellas, and Foundation Medicine, Inc. SJ Klempner holds stock/equity in TP Therapeutics. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

17. Huang B, Chen L, Bao C, et al. The expression status and prognostic significance of programmed cell death 1 ligand


doi: 10.21037/tgh.2019.08.04